Ying Huang resigned as Chief Executive Officer and Board member effective July 24, 2026. The Board appointed Alan Bash, formerly President of CARVYKTI, as Interim Chief Executive Officer and interim principal executive officer. Legend Biotech Corporation is a biotechnology company focused on developing and commercializing CAR-T cell therapies.
